S
Sensorium Therapeutics
Dedicated to enhancing mental well-being and improving the human experience at scale
About Sensorium Therapeutics
Sensorium.bio is a pioneering startup that operates in the mental health sector, specifically in the development of psychoactive medicines. The company's primary objective is to improve mental health by leveraging the complexity of nature and the human brain. They serve a broad range of clients, primarily those suffering from mental illnesses such as anxiety.
Read full description
The company's innovative Biodynamic Discovery Platform™ is a unique blend of advanced chemistry, neuroscience, and machine learning. This platform is used to identify and develop safe and effective plant- and fungi-inspired psychoactive medicines. Their lead candidate, SENS-01, is showing potential to offer a quicker and more durable therapeutic effect for anxiety compared to commonly used treatments.
Sensorium's business model revolves around the research, development, and commercialization of these psychoactive medicines. They generate revenue through the sale of these medicines once they have been approved and are on the market.
The company was founded by a team of experts in chemistry, neuroscience, and psychiatry from Harvard Medical School and Massachusetts General Hospital. It is led by industry leaders with a proven track record in drug discovery and development.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 76.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2025 | $25M | $150M | Dolby Family Ventures · Hatteras Venture Partners · Mission BioCapital | ↗ |
| SERIES AOther financing | Oct 2022 | $30M | $120M | CU Healthcare Innovation Fund · Route 66 Ventures · WPSS.bio · Sante Ventures | ↗ |
Growth signals
Latest recorded traffic for Sensorium Therapeutics is 4.8K monthly website visits, up 33.3% over the last three months. Sensorium Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Sante Ventures
CU Healthcare Innovation Fund
Route 66 Ventures
WPSS.bio
Dolby Family Ventures
Hatteras Venture Partners
Mission BioCapital
Other known investors2 additional known investors
Harvard Medical School
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sensorium Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sensorium Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.